<DOC>
	<DOCNO>NCT00148148</DOCNO>
	<brief_summary>The study compare safety , efficacy pharmacokinetics caspofungin , liposomal amphotericin B combination antifungal treatment adult patient allogeneic haematopoietic stem-cell transplantation granulocytopenia persistent i.g . recurrent fever adequate antibacterial therapy .</brief_summary>
	<brief_title>A Study Caspofungin , Liposomal Amphotericin B Combination Both Patients After Stem-Cell Transplantation</brief_title>
	<detailed_description>This open , randomised , three-arm multicenter phase II clinical trial investigate safety , tolerance plasma pharmacokinetics caspofungin , liposomal amphotericin B combination agent empirical antifungal therapy adult patient follow allogeneic hematopoietic stem cell transplantation . Eligible patient profound granulocytopenia ( ≤ 500 neutrophil granulocyte ) persistent recurrent fever despite broad-spectrum antibacterial therapy minimum 36-48 hour duration . Patients stratify accord type transplantation ( human leukocyte antigen [ HLA ] matched/related versus HLA-mismatched/unrelated ) randomize one follow treatment arm : Caspofungin alone ( 50 mg/day load dose 70 mg day 1 ) , liposomal amphotericin B alone ( 3 mg/kg/day ) , combination caspofungin liposomal amphotericin B ( similar dosage single-drug treatment arm ) . Caspofungin liposomal amphotericin B administer daily intravenous infusion . Serial plasma sample determination pharmacokinetic parameter collect day one four treatment . Safety tolerance randomise intervention evaluate daily , follow last dose study drug 14 day last dose study drug accord current NCI-CTC criterion . Antifungal efficacy survival evaluate follow last dose study drug 14 day last dose study drug . Treatment study drug continue either : 1. treatment limit intolerance toxicity ; 2. hematopoietic engraftment ( ≥ 500 neutrophil granulocyte three consecutive day ) defervescence ; 3. occurrence probable proven invasive fungal infection use current EORTC/MSG criterion . Febrile granulocytopenic patient probable proven invasive fungal infection eligible study . Patients develop probable proven breakthrough infection take study receive standard therapy . Breakthrough infection define probable proven invasive fungal infection occur treatment study medication . Twenty-five patient minimum duration treatment four day randomise per study arm . Patients receive least one dose study drug eligible analysis safety , tolerance pharmacokinetics . For analysis secondary endpoint antifungal efficacy survival , two separate cohort analyse . These include : 1. patient receive least one dose study drug ; 2. patient receive ≥ four dos study drug .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Adults ( &gt; = 18 year age ) granulocytopenia ( absolute number neutrophil granulocyte [ ANC ] : &lt; = 500/µL ) undergone allogeneic haematopoeitic stem cell transplantation immunosuppression cyclosporin A Patients persistent recurrent fever ( oral temperature &gt; = 38.0°C ) granulocytopenia ( absolute neutrophil count &lt; = 500/µL ) adequate antibacterial therapy &gt; = 3648 hour , need empirical antimycotic therapy Already insert least doublelumen central venous catheter administration drug extraction plasma sample Sufficient renal hepatic function Availability negative pregnancy test adequate contraceptive measure female patient childbearing age Availability write informed consent patient respectively legal representative prior information Patients active , possible proven ( MSGEORTC criterion ) invasive fungal infection time enrollment Pregnant nursing patient Patients pathological functional renal hepatic parameter Patients clinical laboratory chemical evidence active venoocclusive disease ( VOD ) Hemodynamically unstable patient life expectancy le 5 day Patients undergoing comedication rifampicin , phenytoin , carbamazepine , phenobarbital , dexamethasone , efavirenz nevirapine Patients prior know serious reaction echinocandinantifungal formulation document allergy amphotericin B Patients condition illness , estimation investigator , distorts study result lead additional risk patient Prior inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Caspofungin</keyword>
	<keyword>Liposomal Amphotericin B</keyword>
</DOC>